{"Clinical Trial ID": "NCT00425854", "Intervention": ["INTERVENTION 1:", "- Cohort B", "Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving an oral dose of Afatinib 50 mg qd"], "Eligibility": ["\u2022 Inclusion criteria:", "Incorporation criteria:", "Women 18 years of age or older", "- Histologically proven breast cancer after failure or relapse of not more than three chemotherapy lines, including adjuvant, regardless of prior metastatic hormone therapy (stage IV);", "HER2-negative (HER2 1+ or negative, HER2 2+ and FISH negative)", "At least one measurable tumour injury (RECIST);", "Availability of tumour samples", "Informed consent in writing in accordance with ICH-GPC guidelines and local law", "Eastern Cooperative Oncology Group (ECOG, R01-0787) Performance Score 0 - 2.", "- Exclusion criteria:", "- Exclusion criteria:", "Active infectious diseases", "Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea", "A serious disease, a concomitant non-oncological disease or mental problems considered by the investigator to be incompatible with the protocol", "Active/symptomatic brain metastases", "- Left cardiac ventricular function with resting ejection fraction < 50% (below the upper limit of normal)", "ASC less than 1500/mm3 platelet count less than 100 000/mm3", "Bilirubine greater than 1.5 mg/dl (>26 and #61549 mol/L, SI unit equivalent)", "AST and ALT greater than 2.5 times the upper limit of normal or greater than 5 times the upper limit of normal in the case of known liver metastases", "- Serum creatinine greater than 1.5 mg/dl (>132 and #61549 mol/L, SI unit equivalent)", "Patients who are sexually active and who do not want to use a medically acceptable method of contraception", "Pregnancy or lactation", "- Concomitant treatment with other experimental medicinal products or other anticancer treatments in this study and/or in the last two/four weeks prior to the first treatment with the test medicinal product.", "Previous treatment with trastuzumab, EGFR or EGFR/HER2 inhibitors is not in accordance with the protocol.", "Active abuse of alcohol or drugs", "Other disease in the last 5 years"], "Results": ["Performance measures:", "- Objective response (OR)", "The OR is defined as the complete response (CR) and the partial response (PR) and has been assessed against the criteria for assessing the response in Solid Tumours version 1.0 (RECIST).", "Timing: Tumor evaluations were performed at week 8, week 16, week 24, and every 8 weeks thereafter.", "Results 1:", "Title of the arm/group: Cohort B", "- Arm/group description: Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving an oral dose of Afatinib 50 mg qd", "Total number of participants analysed: 21", "Type of measurement: Number", "Unit of measure: Participants with OR 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 13/29 (44.83 per cent)", "Anemia 1/29 (3.45%)", "Febrile neutropenia 1/29 (3.45%)", "Meniere's disease 1/29 (3.45%)", "1/29 (3.45%)", "Miose 1/29 (3.45%)", "Abdominal pain 0/29 (0.00 %)", "Diarrhoea 3/29 (10.34 per cent)", "- Dysphagia 0/29 (0.00 %)", "- Nausea 0/29 (0.00 per cent)", "Esophagus stenosis 0/29 (0.00 %)", "Vomiting 2/29 (6.90 per cent)", "- Fatigue 0/29 (0.00 %)"]}